Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivunatamig + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
tivunatamig + carboplatin + pemetrexed is an investigational combination regimen consisting of tivunatamig (PF-08634404 / SSGJ-707), a fully humanized bispecific tetravalent IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A), combined with the platinum-based chemotherapy carboplatin and the antifolate chemotherapy pemetrexed. Developed by 3SBio (and its subsidiary Sunshine Guojian) and licensed globally to Pfizer, this combination is being evaluated as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC). In a Phase II clinical study presented at the ESMO 2026 Congress, the regimen demonstrated a median progression-free survival (mPFS) of 13.8 months and a confirmed objective response rate (cORR) of 77.5% in patients with non-squamous NSCLC, outperforming the control arm of tislelizumab plus carboplatin and pemetrexed.
- Other names
- PF-08634404 + carboplatin + pemetrexedSSGJ-707 + carboplatin + pemetrexedtivunatamib + carboplatin + pemetrexed
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)VEGFR (VEGFR family)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on tivunatamig + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivunatamig + carboplatin + pemetrexed.